Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel.
Bhitta SurapatWarissa KobpetchyokSasisopin KiertiburanakulVanlapa ArnuntasupakulPublished in: International journal of clinical practice (2022)
Low rates of hospitel transfer and mortality were observed in mild-to-moderate COVID-19 patients treated with favipiravir at hospitel. Caution might be required in elderly patients, patients with dyspnea or a loss of taste, and patients receiving a 10-day course of favipiravir or adjunctive corticosteroids because these patients might require further management in the hospitel.